710322-32-0

Upstream product

• 300356-14-3 (R)-2-(3-chloro-4-(methylsulfonyl)phenyl)-3-cyclopentylpropanoic acid 
• 710322-31-9 1-(5-amino-pyrazin-2-yl)-ethanone O-tertbutyl-oxime 
• 710322-29-5 N-(5-acetyl-pyrazin-2-yl)-2,2-dimethyl-propionamide 
• 710322-30-8 N-[5-(1-tert-butoxyimino-ethyl)-pyrazin-2-yl]-2,2-dimethyl-propionamide 

Downstream Products

• 1427744-10-2 C₂₁H₂₅ClN₄O₄S 
• 710321-50-9 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-[5-(1-(Z)-hydroxyimino-ethyl)-pyrazin-2-yl]-propionamide 

Relevant academic research and scientific papers

Identification of RO4597014, a glucokinase activator studied in the clinic for the treatment of type 2 diabetes

To resolve the metabolite redox cycling associated with our earlier clinical compound 2, we carried out lead optimization of lead molecule 1. Compound 4 showed improved lipophilic ligand efficiency and demonstrated robust glucose lowering in diet-induced obese mice without a liability in predictive preclinical drug safety studies. Thus, it was selected as a clinical candidate and further studied in type 2 diabetic patients. Clinical data suggests no evidence of metabolite cycling, which is consistent with the preclinical profiling of metabolism.

5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS

The present invention provides a compound according to formula (I) where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula (I) are also provided, said compounds being glucokinase activators which are useful in the treatment of type II diabetes.